Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
-
Patent number: 12037378Abstract: The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.Type: GrantFiled: May 19, 2020Date of Patent: July 16, 2024Assignee: Novartis AGInventors: Barbara Brannetti, Dattananda Chelur, Brian Granda, Connie Hong
-
Patent number: 12016881Abstract: The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and/or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.Type: GrantFiled: August 9, 2021Date of Patent: June 25, 2024Assignee: NEW YORK UNIVERSITYInventors: Dafna Bar-Sagi, Jane Cullis, Craig Ramirez
-
Patent number: 12018075Abstract: A method of operating a chromatography column is described for use in methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF? antibody SIMPONI® (golimumab). This method involves collecting column outlet signal and accumulated flow parameters at two or more intervals of at least one mobile phase transition front during operation of the chromatography column comprising column packing. A model gamma cumulative distribution curve is calculated based on the collected column outlet signal and accumulated flow parameters for the at least one mobile phase transition front. A height equivalent theoretical plate (HETP) value is calculated for the at least one mobile phase transition front using parameters of the model gamma cumulative distribution curve and the quality of the chromatography column packing is assessed based on the calculated HETP value.Type: GrantFiled: April 19, 2019Date of Patent: June 25, 2024Assignee: Janssen Biotech, Inc.Inventor: Paul Randolph
-
Patent number: 12012451Abstract: The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.Type: GrantFiled: August 19, 2020Date of Patent: June 18, 2024Assignee: The Rockefeller UniversityInventors: Craig Stuart Pace, David D. Ho
-
Patent number: 12012464Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.Type: GrantFiled: October 6, 2021Date of Patent: June 18, 2024Assignee: NOVARTIS AGInventors: Maximilian Aigner, Alexander Wolfgang Koch, Markus Waldhuber
-
Patent number: 12012444Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins.Type: GrantFiled: March 1, 2023Date of Patent: June 18, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn M. Lawrence, Amy S. Johnson, Meghan Casey, Jaimie Grapel
-
Patent number: 11987609Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.Type: GrantFiled: September 21, 2018Date of Patent: May 21, 2024Assignee: DINGFU BIOTARGET CO., LTD.Inventors: Ting Xu, Yan Luan, Jianjian Peng, Shilong Fu
-
Patent number: 11981737Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.Type: GrantFiled: May 17, 2019Date of Patent: May 14, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Jens Fischer, Meher Majety, Stefan Dengl, Georg Tiefenthaler, Stefan Klostermann, Claudia Kirstenpfad, Esther Koenigsberger, Francesca Ros
-
Patent number: 11975070Abstract: The present invention pertains to affinity chromatography isolation and purification of extracellular vesicles (EVs). The EVs of the present invention are engineered to enable highly specific binding to e.g. chromatography matrices, which is highly useful for affinity-based isolation and purification of EVs from complex biological fluids such as cell culture medium or biological fluids.Type: GrantFiled: October 23, 2018Date of Patent: May 7, 2024Assignee: Evox Therapeutics LtdInventors: Oscar Wiklander, Andre Gorgens
-
Patent number: 11964005Abstract: The present disclosure is directed to methods of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject.Type: GrantFiled: March 16, 2022Date of Patent: April 23, 2024Assignee: Receptos, LLCInventors: Sarah Harris, Erin Babcock, Cristian Rodriguez
-
Patent number: 11958894Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.Type: GrantFiled: June 23, 2023Date of Patent: April 16, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn M. Lawrence, Amy S. Johnson, Meghan Casey, Jaimie Grapel
-
Patent number: 11952421Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: GrantFiled: October 8, 2015Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Patent number: 11952424Abstract: The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence. The invention also relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein at least one additional binding domain comprises a CH1 region and is connected to the base antibody portion by said linker, linking a variable region of the base antibody portion and the CH1 region, and wherein the multivalent antibody binds to at least three different epitopes.Type: GrantFiled: March 29, 2019Date of Patent: April 9, 2024Assignee: merus n.v.Inventors: Cornelis Adriaan de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 11953503Abstract: Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.Type: GrantFiled: January 14, 2019Date of Patent: April 9, 2024Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Harald Althaus, Thorsten Keller
-
Patent number: 11945880Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: December 3, 2021Date of Patent: April 2, 2024Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 11945876Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.Type: GrantFiled: June 15, 2022Date of Patent: April 2, 2024Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
-
Patent number: 11939392Abstract: The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.Type: GrantFiled: December 21, 2021Date of Patent: March 26, 2024Assignee: Aptevo Research and Development LLCInventors: Gabriela Hernandez-Hoyos, Elaine T. Sewell, Catherine J. McMahan, David Bienvenue, John W. Blankenship, Danielle Mitchell, Peter Pavlik
-
Patent number: 11939372Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: GrantFiled: October 23, 2019Date of Patent: March 26, 2024Assignee: AMGEN INC.Inventor: Christopher J. Paszty
-
Patent number: 11912750Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.Type: GrantFiled: November 9, 2017Date of Patent: February 27, 2024Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey
-
Patent number: 11904004Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: GrantFiled: June 9, 2020Date of Patent: February 20, 2024Assignees: INSERM, UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CNRS, UNIVERSITE DE NANTESInventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
-
Patent number: 11905313Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.Type: GrantFiled: November 27, 2018Date of Patent: February 20, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services.Inventor: Surender Khurana
-
Patent number: 11891440Abstract: The present invention provides for recombinant antibodies having the features of ruminant early colostrum antibodies that impart resistance to proteases and intestinal digestion. It is a feature of the present invention that when administered to animals including humans, pharmaceutical compositions comprising the novel recombinant antibodies of the present invention, advantageously exhibit resistance to proteases and intestinal digestion. Thus, pharmaceutical compositions of the recombinant antibodies of the invention may be used to deliver antibody therapeutics particularly by oral delivery to the gastrointestinal tract when oral delivery is advantageous.Type: GrantFiled: September 29, 2016Date of Patent: February 6, 2024Assignee: CIRCLE33 LLCInventor: Randall Edward Burton
-
Patent number: 11884739Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.Type: GrantFiled: March 24, 2021Date of Patent: January 30, 2024Assignee: ACADEMIA SINICAInventors: Chi-Huey Wong, Chung-Yi Wu, Ming-Hung Tsai
-
Patent number: 11866505Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).Type: GrantFiled: August 26, 2022Date of Patent: January 9, 2024Assignees: PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBHInventors: Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
-
Patent number: 11857625Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.Type: GrantFiled: November 13, 2018Date of Patent: January 2, 2024Assignee: UCB BIOPHARMA SRLInventors: Sandrine Durran, Andrew Jeffrey Yates
-
Patent number: 11859011Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: October 18, 2021Date of Patent: January 2, 2024Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 11851502Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: GrantFiled: May 21, 2018Date of Patent: December 26, 2023Assignee: Ichnos Sciences SAInventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
-
Patent number: 11845793Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.Type: GrantFiled: October 31, 2016Date of Patent: December 19, 2023Assignee: NBE-THERAPEUTICS AGInventors: Lorenz Waldmeier, Ulf Grawunder, Roger Beerli
-
Patent number: 11840577Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.Type: GrantFiled: July 30, 2020Date of Patent: December 12, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Meike Hutt, Felix Unverdorben, Sebastian Bunk, Dominik Maurer, Martin Hofmann, Gabriele Pszolla, Sara Yousef, Claudia Wagner, Frank Schwoebel, Heiko Schuster
-
Patent number: 11834512Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.Type: GrantFiled: May 3, 2021Date of Patent: December 5, 2023Assignee: The Regents of the University of CaliforniaInventor: Arjun Deb
-
Patent number: 11834716Abstract: Disclosed is a method for predicting whether esophageal cancer is sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody. Specifically, the method predicts by measurement of expression at the RNA level, or at the protein level, of at least one biomarker selected from SDC2, PTGES, NCF2, NOXA1, CARD6 and GNAZ in a tumor sample.Type: GrantFiled: June 12, 2018Date of Patent: December 5, 2023Assignee: Canbridge Life Sciences LTDInventors: James Qun Xue, Jing Wang, Ya Gao, Huaizhong Hu
-
Patent number: 11827672Abstract: Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.Type: GrantFiled: March 29, 2019Date of Patent: November 28, 2023Assignee: Eureka Therapeutics, Inc.Inventors: Jun Cui, Pengbo Zhang, Yiyang Xu, Shan Li, Yixiang Xu, Guangyan Xiong, Hongruo Yun, Lianxing Liu, Xiaomei Ge, Shaohua Xu, Hong Liu, Javier Morales
-
Patent number: 11827713Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.Type: GrantFiled: June 27, 2018Date of Patent: November 28, 2023Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Lei Yang, Pingyan Wang, Qingyan Li
-
Patent number: 11827697Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.Type: GrantFiled: February 2, 2019Date of Patent: November 28, 2023Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Yaping Yang, Nanmeng Song, Wenchu Xiao, Zhenlei Li, Lina Zhang, Mingyue Gu, Chunguang Zhan, Jiawang Liu, Maengsup Kim
-
Patent number: 11827720Abstract: The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.Type: GrantFiled: August 15, 2017Date of Patent: November 28, 2023Assignee: F-star Therapeutics LimitedInventors: Florian Ruker, Gottfried Himmler, Gordana Wozniak-Knopp
-
Patent number: 11827671Abstract: The invention provides methods for treating Systemic Sclerosis by administering a dual-V region bispecific antibody that specifically binds IL-4 and IL-13.Type: GrantFiled: May 22, 2020Date of Patent: November 28, 2023Assignee: SANOFIInventors: Christina Soubrane, Corinne Esperet, Frederic Marrache, Peter Wung
-
Patent number: 11820830Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: GrantFiled: July 29, 2020Date of Patent: November 21, 2023Assignee: Xencor, Inc.Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Patent number: 11813307Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).Type: GrantFiled: June 4, 2018Date of Patent: November 14, 2023Assignees: MERCK PATENT GMBH, ABLYNX NVInventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
-
Patent number: 11795221Abstract: Provided are novel fully human monoclonal antibodies that bind to human LAG-3. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-LAG-3 antibodies, expression vectors and host cells used for the expression of anti-LAG-3 antibodies. The invention further provides the methods for validating the function of antibodies in vitro. The antibodies of invention provide a potent agent for the treatment of multiple cancers via modulating human immune function.Type: GrantFiled: February 27, 2019Date of Patent: October 24, 2023Assignee: WUXI BIOLOGICS IRELAND LIMITEDInventors: Yong Zheng, Qiong Wu, Jing Li
-
Patent number: 11786529Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.Type: GrantFiled: November 29, 2018Date of Patent: October 17, 2023Assignee: BEIGENE SWITZERLAND GMBHInventors: James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang
-
Patent number: 11787873Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: January 16, 2020Date of Patent: October 17, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Patent number: 11787868Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.Type: GrantFiled: December 22, 2020Date of Patent: October 17, 2023Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
-
Patent number: 11773175Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.Type: GrantFiled: July 30, 2021Date of Patent: October 3, 2023Assignee: KYMAB LIMITEDInventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
-
Patent number: 11773179Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.Type: GrantFiled: January 13, 2021Date of Patent: October 3, 2023Assignee: VISTERRA, INC.Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
-
Patent number: 11718678Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.Type: GrantFiled: March 2, 2020Date of Patent: August 8, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
-
Patent number: 11707056Abstract: The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion.Type: GrantFiled: March 19, 2014Date of Patent: July 25, 2023Assignee: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee
-
Patent number: 11702473Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.Type: GrantFiled: November 14, 2019Date of Patent: July 18, 2023Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
-
Patent number: 11697690Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: March 29, 2021Date of Patent: July 11, 2023Assignee: GENZYME CORPORATIONInventors: Luis Avila, Clark Pan, Huawei Qiu, Qun Zhou
-
Patent number: 11685776Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.Type: GrantFiled: March 1, 2018Date of Patent: June 27, 2023Assignee: Novartis AGInventors: Regis Cebe, Sebastien Irigaray, Darko Skegro
-
Patent number: 11673972Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: December 16, 2020Date of Patent: June 13, 2023Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee